Vyome Holdings, Inc

Vyome Holdings is a clinical-stage biotechnology company developing therapeutic products focused on immuno-inflammatory and rare diseases. Headquartered in Cambridge, Massachusetts, the company was founded in 2017 and operates primarily in the United States with a global market orientation. The company's pipeline targets conditions at the intersection of immunology and inflammation, though it remains in early clinical development stages without approved commercial products.

As a clinical-stage entity, Vyome does not currently generate meaningful revenue from product sales. The company operates with a lean organizational structure of 17 full-time employees, typical for biotechnology firms in pre-commercialization phases. Research and development activities represent the primary operational focus, with the company advancing its therapeutic candidates through clinical evaluation and regulatory processes.

The company is incorporated in Delaware and listed on Nasdaq, providing access to public capital markets. Geographic operations center on the United States, though the company pursues development opportunities in global markets. Given its clinical-stage status and small employee base, Vyome remains dependent on capital raises and strategic partnerships to fund ongoing development and advance its pipeline candidates.